https://www.selleckchem.com/pr....oducts/verubecestat.
63 (99.8% CI 0.44 to 0.89); stratified log-rank 2-sided p-value less then 0.0001). The median OS was not reached for the nivolumab + ipilimumab group and was 25.95 months for the sunitinib group. The OS rates were 89.5% and 86.2% at 6 months, and 80.1% and 72.1% at 12 months in the nivolumab +ipilimumab and the sunitinib groups, respectively. K-M curves separated after approximately 3 months, favouring nivolumab + ipilimumab. This was not mirrored in the favourable-risk patients where no statistically significant difference was obs
Me gusta
Comentario
Compartir
